Mizuho raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $13 from $11 and keeps an Outperform rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- CRVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Corvus Pharmaceuticals’ Soquelitinib Study: A Potential Game-Changer for Atopic Dermatitis
- Corvus Pharmaceuticals’ Phase 3 Study on Soquelitinib: A Potential Game-Changer in Lymphoma Treatment
- Corvus Pharmaceuticals initiated with an Overweight at Barclays
- Corvus Pharmaceuticals Appoints David Moore as Director